CSL
OrganizationHeard in 22 episodes across 7 shows since Jul 2026
CSL is a global biotechnology company headquartered in Australia. Through CSL Behring, CSL Seqirus, and CSL Vifor, it develops and manufactures plasma-derived and recombinant therapies, vaccines, and medicines for serious and chronic diseases.
Episodes
This week
Expert statements
Share of the conversation
Mentions of CSL per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 24 | 0.11‰ | 1 |
| Aug 25 | 0.08‰ | 1 |
| Aug 26 | 0.06‰ | 1 |
| Sep 2 | 0.03‰ | 3 |
| Sep 4 | 0.04‰ | 1 |
| Sep 16 | 0.02‰ | 2 |
| Sep 17 | 0.05‰ | 3 |
| Sep 18 | 0.09‰ | 5 |
| Sep 20 | 0.11‰ | 2 |
| Oct 5 | 0.01‰ | 1 |
| Oct 6 | 0.02‰ | 1 |
| Oct 29 | 0.01‰ | 1 |
| Nov 3 | 0.02‰ | 1 |
| Nov 16 | 0.01‰ | 1 |
Email alert
Email me when CSL comes up on a podcast
One email a week at most, with the new episodes that mention CSL. Free, no account needed, unsubscribe in one click.
What experts have said about CSL
11 statements · 9 positive · 2 negative
CSL is an industry-leading business in blood plasma and vaccines.
“It's a wonderful business, blood plasma vaccines, all that sort of stuff. It's an industry leader.”
Open the episode · Rates rise around the world, why the Aged Pension isn't enough & Pimp my Portfolio with Owen RaskListen at 31:42
CSL staged a major rally after becoming deeply undervalued.
“We were maximum CSL across all our funds. And since then, it's had this astonishing rally.”
Open the episode · Riding the rebound in CSL, Cochlear and finding the next opportunityListen at 14:00
CSL shares rose 38% in one month after its reporting result.
“the stock just, you know, it was up 38% in a month.”
Open the episode · Hofflin: Big moves are creating great value on the ASXListen at 14:14
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
22 episodes featuring CSL, newest first
- Nov 16, 2026
Luke Laretive challenges small-cap certaintyEquity Mates Investing PodcastNov 16, 2026 - Nov 3, 2026
Reliable income demands more than chasing high dividendsEquity Mates Investing PodcastNov 3, 2026 - Oct 29, 2026
AI boom exposes the cost of capital-hungry growthStock TakeOct 29, 2026 - Oct 6, 2026
China’s biotech assets go global as Medicare pricing models shrinkBioCentury This WeekOct 6, 2026 - Oct 5, 2026
Australia’s policy bets collide with markets, technology and growthThe Contrarians with Adam and AdirOct 5, 2026 - Sep 20, 2026
Australia’s retirement assumptions meet a tougher investing realityEquity Mates Investing PodcastSep 20, 2026